FMR LLC held its position in shares of Axovant Sciences Ltd. (NYSE:AXON) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 677,170 shares of the biotechnology company’s stock at the end of the first quarter. FMR LLC’s holdings in Axovant Sciences were worth $10,117,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in AXON. JPMorgan Chase & Co. raised its stake in shares of Axovant Sciences by 4.1% in the first quarter. JPMorgan Chase & Co. now owns 489,024 shares of the biotechnology company’s stock worth $7,306,000 after buying an additional 19,129 shares in the last quarter. State Street Corp raised its stake in shares of Axovant Sciences by 10.0% in the fourth quarter. State Street Corp now owns 353,401 shares of the biotechnology company’s stock worth $4,391,000 after buying an additional 32,164 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in shares of Axovant Sciences by 77.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 160,000 shares of the biotechnology company’s stock worth $2,391,000 after buying an additional 70,000 shares in the last quarter. C WorldWide Group Holding A S bought a new stake in shares of Axovant Sciences during the first quarter worth $1,637,000. Finally, Nationwide Fund Advisors raised its stake in shares of Axovant Sciences by 70.9% in the first quarter. Nationwide Fund Advisors now owns 83,543 shares of the biotechnology company’s stock worth $1,248,000 after buying an additional 34,654 shares in the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.
Shares of Axovant Sciences Ltd. (NYSE AXON) traded down 0.19% on Friday, reaching $21.01. 463,998 shares of the company traded hands. The company has a 50-day moving average of $22.68 and a 200-day moving average of $19.46. Axovant Sciences Ltd. has a 1-year low of $11.01 and a 1-year high of $26.49. The stock’s market capitalization is $2.26 billion. Axovant Sciences also saw some unusual options trading activity on Wednesday. Stock traders acquired 11,388 put options on the company. This is an increase of approximately 1,108% compared to the typical volume of 943 put options.
Axovant Sciences (NYSE:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.12. Analysts anticipate that Axovant Sciences Ltd. will post ($2.41) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece was posted by BNB Daily and is the sole property of of BNB Daily. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/fmr-llc-has-10117000-position-in-axovant-sciences-ltd-axon-updated-updated-updated.html.
AXON has been the subject of a number of research reports. Cowen and Company reiterated an “outperform” rating and set a $30.00 target price on shares of Axovant Sciences in a research note on Wednesday, June 21st. Jefferies Group LLC started coverage on shares of Axovant Sciences in a research note on Monday, July 10th. They set a “buy” rating and a $40.00 target price for the company. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Saturday. Zacks Investment Research downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, CIBC boosted their price objective on shares of Axovant Sciences from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, June 14th. Three research analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $27.75.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.